Impact of therapy in patients with hematologic malignancies on seroconversion rates after sars-cov-2 vaccination

HIGHLIGHTS

  • who: The Oncologist and collaborators from the Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey , Bone Marrow Transplantation Unit, Hacettepe University Cancer Institute, Ankara, Turkey , Immuno-Oncology Program and , Task Force, Ares Pharmaceuticals, StPaul, MN, USA , have published the paper: Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination, in the Journal: (JOURNAL)
  • what: The authors report a systematic literature review regarding the antibody response to SARS-CoV-2 vaccination in patients with hematologic malignancies . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?